Pharmacological properties of the drug Hexasprey
Antiseptic, analgesic, anti-inflammatory drug for topical use in otolaryngology, containing biclotymol (2,2-methylene-bis-(6-chlorothymol)). It is a phenol derivative with antibacterial activity against staphylococci, streptococci, micrococci and corynebacteria. The mechanism of action is due to the ability to coagulate proteins of microbial cells. In addition to antibacterial, it also has anti-inflammatory and local anesthetic effects. The drug is absorbed very slowly through the mucous membrane, which ensures its long-term presence in the oral cavity.
Hexasprey
Hexasprey (active ingredient - biclotymol) is an antiseptic drug for topical use in otolaryngological practice, which has an analgesic and anti-inflammatory effect. This antimicrobial drug is used for infectious and inflammatory lesions of the mucous membrane of the oral cavity, pharynx and larynx. Its spectrum of action covers such traditional pathogens of infections of the upper respiratory tract as staphylococci, streptococci and corynebacteria. Discomfortable sensations in the throat, including soreness and pain when swallowing, are a traditional complaint heard in the office of a local therapist during the cold season. And the reason for this is not only hypothermia, but also the invasion of the body through the “entrance gate” of the oral cavity by an army of bacteria and viruses. Therefore, in this “icy winter season,” the question of choosing a drug to eliminate a sore throat, which is the first to take on a bacterial-viral attack, becomes more relevant than ever. One of the most common seasonal diseases during this period is pharyngitis. As morbidity statistics show, about 70% of catarrhal pharyngitis develop as a consequence of a viral infection. At the same time, a viral lesion of the pharyngeal mucosa in most cases is followed by a bacterial lesion: the immune system, weakened as a result of a viral attack, is not able to mobilize in time to eliminate pathogenic bacteria that enter the body. Therefore, it is very important, even at the first alarm bells (dryness and sore throat, pain when swallowing), to immediately begin complex drug therapy aimed at eliminating both viral and bacterial pathogens. Mild forms of infections are usually treated with local antimicrobial, analgesic and anti-inflammatory drugs. All these qualities are inherent in the original drug Hexaspray from the French pharmaceutical industry, which is suitable for both pathogenetic (elimination of the cause of the disease) and symptomatic (elimination of signs of the disease) treatment. The active ingredient in hexaspray, biclotymol, has the ability to coagulate proteins of bacterial cells, exhibiting antimicrobial activity against traditional pathogens of acute respiratory infections.
Hexaspray is available in the form of an aerosol, which ensures ease of use and rapid onset of the therapeutic effect, because the rate of absorption of the active component through the mucous membrane increases. It should be noted that hexaspray does not contain dyes that can cause allergic reactions.
Another aspect that increases the relevance of the search for new drugs for the treatment of infectious and inflammatory diseases of the mucous membrane of the oral cavity, larynx and pharynx is the irrational use of antibiotics, as a result of which many bacterial strains resistant to antibiotic therapy have appeared. As noted above, hexaspray was proposed as one of these drugs, which, in addition to the classic “staphylococcus + streptococcus” combination, extends its effect to, among other things, Neisseria, Corynebacterium and Haemophilus influenzae. This drug has both bacteriostatic and bactericidal effects, i.e. it not only suppresses the growth and development of microorganisms, but also destroys them, destroying the mucopolysaccharide shells of bacteria within 10 minutes after application. In one of the clinical trials, the effectiveness of hexaspray was assessed in patients suffering from acute pharyngitis, complicated by chronic glossitis and tonsillitis. All patients of the main group injected the drug three times a day for 5-7 days. Patients in the control group received traditional drug treatment in such cases. When analyzing the results of the study, it was found that a rapid and pronounced regression of inflammatory symptoms was achieved in 92% of patients in the main group and in 64% of patients in the control group, which confirmed the greater effectiveness of hexaspray in comparison with standard treatment methods.
When using hexaspray, it is not recommended to use other drugs for topical use in the oral cavity. If after 5 days of drug therapy there is no significant improvement in the condition, you need to consult a doctor so that he can make adjustments to the treatment tactics.
Special instructions for the use of Hexasprey
Using the drug for more than 5 days may cause disruption of the normal microflora of the oral cavity. The simultaneous use of other antiseptics should be avoided, since undesirable interactions (antagonism, inactivation) are possible. If the patient’s condition has worsened, in particular the body temperature has increased or there has been no improvement within 5 days, it is necessary to re-examine and change the treatment tactics. During pregnancy and breastfeeding. Adequate and well-controlled studies of the safety of the drug during pregnancy and breastfeeding have not been conducted.
Hexasprey aerosol for topical use 2.5% 30 g No. 1
Name
Hexasprey air.d/local.prim. 2.5% in fl 30g in pack No. 1
Description
A homogeneous suspension of white with a yellowish tint with a characteristic anise odor.
Main active ingredient
Biclotymol
Release form
Aerosol
Dosage
2,5%
special instructions
Keep the bottle upright during use. Shake the bottle before use. The therapy does not justify long-term treatment, especially since prolonged use of the drug for more than 5 days can disrupt the normal microflora of the mouth and throat with the risk of bacterial or fungal spread. If symptoms do not resolve within 5 days and/or are accompanied by fever, treatment should be reconsidered. The simultaneous or sequential use of antiseptics with biclotymol should be avoided, taking into account possible interactions (antagonism, inactivation). Soy lecithin may cause allergic reactions. The drug contains a small amount of alcohol, less than 100 mg per dose. Due to the content of methyl parahydroxybenzoate (E218), it can cause allergic reactions (including delayed ones).
Pharmacodynamics
Antimicrobial drug for topical use with antimicrobial effect. Biclotymol belongs to the class of biphenols. Biclotymol is active against gram-positive microorganisms under the following conditions: 15 minutes from contact to maximum concentration (900/0).
Pharmacokinetics
Unknown. Non-clinical safety data Not known.
Indications for use
The drug is indicated for the local treatment of infectious and inflammatory diseases of the mucous membrane of the oral cavity and pharynx, which are not accompanied by an increase in body temperature. If general signs of a bacterial infection occur, systemic antibiotics should be prescribed.
Directions for use and doses
Adults and children over 6 years of age: 2 sprays 3 times a day, regardless of meals. Treatment should be limited to 5 days.
Use during pregnancy and lactation
There is no reliable data on the teratogenic effect in animals. Clinically, no teratogenic effect or fetotoxicity effect has been demonstrated in women so far. However, monitoring of pregnant women exposed to biclotymol is not sufficient to exclude any risk. Therefore, as a precaution, it is preferable not to use biclotymol.
Interaction with other drugs
Avoid simultaneous use of other local agents.
Contraindications
Children's age up to 6 years. Hypersensitivity to the components of the drug.
Compound
Per bottle Active ingredients: Biclotymol 0.75 g Excipients: Benzyl alcohol 0.50 g Disodium edetate 0.0025 g Methyl parahydroxybenzoate (E218) 0.025 g Star anise oil 0.03 g Ammonium glycyrrhizinate 0.02 g Sodium saccharinate 0.05 g Avicel RC 591 (microcrystalline cellulose and sodium carmellose) 0.30 g Soy lecithin 0.90 g Glycerol 1.06 g Ethanol 96% 1.06 g Water 30.00 g
Overdose
No data on overdose
Side effect
During treatment with biclotymol, the following adverse reactions were observed, which are presented in accordance with the MedRA classification by body system and frequency of occurrence and are conventionally defined as follows: Very common (? 1/10) Frequent (? 1/100,
Storage conditions
At a temperature not exceeding 25 °C, out of the reach of children.
Hexaspray
Manufacturer: Laboratoires BOUCHARA-RECORDATI (France)
◊ aerosol for local use. approx. 2.5%: fl. 30 g with spray valve Reg. No.: P N006694
Clinical and pharmacological group:
Antiseptic for topical use in ENT practice
Release form, composition and packaging
◊Aerosol for topical use
in the form of a homogeneous suspension of white color with a yellowish tint, with a characteristic odor of anise.
| 1 fl. (30 g) | |
| biclotymol | 750 mg |
Excipients:
benzyl alcohol, disodium edetate, methylparaben, anise oil, ammonium glycyrrhizinate, sodium saccharin, Avicel RC 591 (microcrystalline cellulose and sodium carboxymethylcellulose), soy lecithin, glycerol, ethanol 95%, purified water.
30 g - glass bottles with a plastic coating (1) with a spray valve - cardboard packs.
Description of the active components of the drug "Hexasprey"
pharmachologic effect
Antiseptic for local use in ENT practice. Active regarding
staphylococci, streptococci and corynebacteria, has a local anesthetic and anti-inflammatory effect.
When applied topically, it has a long-lasting effect.
Indications
Local treatment of infectious and inflammatory diseases of the oral cavity, pharynx and larynx caused by microorganisms sensitive to biclotymol, including:
- acute and chronic pharyngitis;
- pharyngolaryngitis;
- tonsillitis;
— condition after tonsillectomy;
- glossitis.
Dosage regimen
The drug is prescribed by inhalation, 2 injections 3 times a day, regardless of meals.
During inhalation, the bottle should be held vertically. The bottle must be shaken before use.
Side effect
Maybe:
allergic reactions.
Contraindications
- children under 6 years of age;
- hypersensitivity to the components of the drug.
Pregnancy and lactation
The drug can be used during pregnancy and lactation (breastfeeding).
Application for children
Contraindication: children under 6 years of age.
special instructions
If within 5 days the therapeutic effect is absent or weak, the therapy used should be reconsidered.
Overdose
Currently, no cases of overdose of Hexasprey have been reported.
Drug interactions
Concomitant use of other topical oral medications should be avoided.
Conditions for dispensing from pharmacies
The drug is approved for use as a means of OTC.
Storage conditions and periods
The drug should be stored out of the reach of children at a temperature not exceeding 25°C. Shelf life: 5 years.
Drug interactions
Concomitant use of other topical oral medications should be avoided.
